natgillin/translations-raw huggingface dataset:
(Starpakning 21 tabletter, valproat tillægsbehandling - kaldender pakning viser dagnumre): 1 3 5 7 9 11 13 (en lomme)
(Starter pack 21 tablets, valproate add-on therapy - calender pack showing day numbers): 1 3 5 7 9 11 13 (one pocket)
Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin eller har brugt det for nylig.
Tell your doctor or pharmacist if you're taking any other medicines, if you've taken any recently, or if you start taking new ones - these include herbal medicines or other medicines you bought without a prescription.
150 mg/dag
150 mg/day
Lamictal indeholder:
Do not take Lamictal:
“Voksne og børn over 12 år {Handelsnavn} er indiceret som monoterapi eller tillægsbehandling af epilepsi med partielle anfald og generaliserede anfald, herunder tonisk-kloniske anfald og anfald ved Lennox-Gastaut syndrom”.
“Adults and children above 12 years {Tradename} is indicated for use as adjunctive or monotherapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome”.
• Hævelser i ansigtet (ødem) eller hævede kirtler på halsen, i armhulerne eller i lysken (lymfadenopati)
• swelling around the face (oedema) or swollen glands in the neck, armpit or groin
De er påtrykt 'GS CL2' på den ene side og '5' på den anden side.
They are marked ‘GS CL2' on one side; and ‘5' on the other.
• Hyppigere anfald hos patienter med epilepsi
• in people who already have epilepsy, seizures happening more often
Dispergibel tablet / tyggetablet.
Dispersible/chewable tablet.
Bipolar lidelse
Bipolar disorder
Lamictal kan anvendes sammen med andre lægemidler til behandling af disse tilstande.
• For children aged between 2 and 12 years, Lamictal can be used with other medicines, to treat those conditions.
Hjælpestof: Hver tablet indeholder 109,0 mg lactose.
Excipient: Each tablet contains 109.0 mg lactose.
Hos patienter, som får samtidig behandling med valproat, skal der benyttes et hensigtsmæssigt behandlingsregimen (se pkt.
In patients receiving concomitant therapy with valproate, the appropriate treatment regimen should be used (see section 4.2).
Hos patienter, som får samtidig behandling med lopinavir/ritonavir, skal der benyttes et hensigtsmæssigt behandlingsregimen (se pkt.
In patients receiving concomitant therapy with lopinavir/ritonavir, the appropriate treatment regimen should be used (see section 4.2).
Hos patienter, som får samtidig behandling med rifampicin, skal der benyttes et hensigtsmæssigt behandlingsregimen (se pkt.
In patients receiving concomitant therapy with rifampicin, the appropriate treatment regimen should be used (see section 4.2).
Litauen The Wellcome Foundation Limited Glaxo Wellcome House
Lithuania The Wellcome Foundation Limited
Der blev dog observeret reduceret føtalvægt og forsinket forbening af skelettet ved eksponeringsniveauer under eller lig med den forventede kliniske eksponering.
In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but reduced foetal weight and retarded skeletal ossification were observed, at exposure levels below or similar to the expected clinical exposure.
Startpakning med 42 dispergible tabletter / tyggetabletter.
Starter pack of 42 dispersible/chewable tablets.
Under kliniske forsøg med monoterapi: Ikke almindelig:
During monotherapy clinical trials: Uncommon:
Hjælpestof: Hver tablet indeholder 46,9 mg lactose.
Excipient: Each tablet contains 46.9 mg lactose.
“Børn på 2 til 12 år {Handelsnavn} er indiceret som tillægsbehandling af epilepsi med partielle anfald og generaliserede anfald, herunder tonisk-kloniske anfald og anfald ved Lennox-Gastaut syndrom”.
“Children 2 to 12 years {Tradename} is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome”.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN [Se bilag I - udfyldes nationalt]
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
200-400 mg/dag (fordelt på to doser)
200 − 400 mg/day (two divided doses)
Almene symptomer og reaktioner på administrationsstedet Under kliniske forsøg vedrørende bipolar sygdom: Almindelig:
General disorders and administration site conditions During bipolar disorder clinical trials: Common:
Lamictal kan anvendes alene eller sammen med andre lægemidler til behandling af epilepsi.
• For adults and children aged 13 years and over, Lamictal can be used on its own or with other medicines, to treat epilepsy.
Hvid til offwhite, aflang, bikonveks tablet med solbærlugt påtrykt "GS CL2" på den ene side og "5" på den anden side.
White to off-white, elongated, biconvex tablet with a blackcurrant odour, marked “GS CL2” on one side and “5” on the other.
Knogler, led, muskler og bindevæv Meget sjælden:
Musculoskeletal and connective tissue disorders Very rare:
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 0,3 mg/kg hver eller hver anden uge, indtil den optimale respons er opnået, og vedligeholdelsesdosis må maksimalt være 200 mg/dag
To achieve maintenance, doses may be increased by maximum of 0.6 mg/kg every one to two weeks until optimal response is achieved, with a maximum of maintenance dose of 200 mg/day
Startpakning 42 dispergible tabletter / tyggetabletter, ikke-valproat tillægsbehandling
Starter pack 42 dispersible/chewable tablets, non-valproate add-on therapy
De er påtrykt 'GS EC5' på den ene side og '200' på den anden side.
They are marked ‘GSEC5' on one side; and ‘200' on the other.
25 mg tabletter:
25 mg tablets:
De er påtrykt 'GS CL7' på den ene side og '100' på den anden side.
They are marked ‘GSCL7' on one side; and ‘100' on the other.
Der er ikke enighed om, hvilket lægemiddel der bør anvendes som den indledende behandling.
There is no consensus on which drug should be used as initial treatment; however, the data analysed do not exclude that lamotrigine could be the initial agent.
Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden.
If you have any unwanted Lamictal tablets, don't dispose of them in your waste water or your household rubbish.
Pakninger med 30 dispergible tabletter / tyggetabletter.
Packs of 30 dispersible/chewable tablets.
De er påtrykt 'GS CX7' på den ene side og '50' på den anden side.
They are marked ‘GSCX7' on one side; and ‘50' on the other.
Sådan skal du tage Lamictal
HOW TO TAKE LAMICTAL
Hver Lamictal 200 mg tablet indeholder 200 mg lamotrigin.
Each Lamictal 200 mg tablet contains 200 mg lamotrigine.
Hjælpestof: Hver tablet indeholder 93,9 mg lactose.
Excipient: Each tablet contains 93.9 mg lactose.
Lamictal kan også anvendes sammen med andet medicin til behandling af de anfald, der opstår i forbindelse med tilstanden Lennox-Gastautsyndrom, - Hos børn i alderen 2-12 år.
Lamictal can also be used with other medicines to treat the seizures that occur with a condition called Lennox-Gastaut syndrome.
• Bupropion, der anvendes til behandling af psykiske problemer eller til rygeafvænning.
• bupropion, used to treat mental health problems or to stop smoking Î Tell your doctor if you are taking any of these.
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 25-50 mg hver eller hver anden uge, indtil den optimale respons er opnået
To achieve maintenance, doses may be increased by maximum of 25 - 50 mg every one to two weeks until optimal response is achieved
(Startpakning 42 tabletter, monoterapi - kalender pakning viser dagnumre): 1 2 3 4 5 6 7 (en lomme)
(Starter pack 42 tablets, monotherapy - calender pack showing day numbers): 1 2 3 4 5 6 7 (one pocket)
Dispergible tabletter / tyggetabletter:
Dispersible/chewable tablets:
Hver pakning med blistere indeholder 30, 56 eller 100 tabletter.
Each pack contains blisters of 30, 56 or 100 tablets.
25 mg Tabletter
25 mg Tablet
Lægemidler, der signifikant hæmmer glukuronidering af lamotrigin
Medicinal products that significantly inhibit glucuronidation of lamotrigine
200 mg/dag 300 mg/dag 400 mg/dag
200 mg/day 300 mg/day 400 mg/day
Du skal dog være opmærksom på, at de kan være alvorlige.
But you must be aware that they are potentially serious - so, if you notice any of these symptoms:
Lamictal 5 mg dispergible tabletter / tyggetabletter er aflange med buede sider.
Lamictal 5 mg dispersible/chewable tablets are elongated with curved sides.
400 mg/dag 300 mg/dag 200 mg/dag
400 mg/day 300 mg/day 200 mg/day
Hver Lamictal 100 mg tablet indeholder 100 mg lamotrigin.
Each Lamictal 100 mg tablet contains 100 mg lamotrigine.
Pakninger med 30, 50, 56, 60, 90 eller 100 tabletter.
Packs of 30, 50, 56, 60, 90 or 100 tablets.
Hver Lamictal 25 mg tablet indeholder 25 mg lamotrigin.
Each Lamictal 25 mg tablet contains 25 mg lamotrigine.
Hver pakning med blistere indeholder 10, 14, 28, 30, 50 eller 56 tabletter.
Each pack contains blisters of 10, 14, 28, 30, 50 or 56 tablets.
Dette dosisregimen skal følges, når andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin, tilføjes
This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are added
Pakninger med 14, 21, 30, 42, 50, 56 eller 100 tabletter.
Packs of 14, 21, 30, 42, 50, 56 or 100 tablets.
Lamictal 100 mg tabletter er påtrykt 'GS SEE5' på den ene side og '100' på den anden side.
Lamictal 100 mg tablets are marked ‘GSEE5' on one side and ‘100' on the other.
Lamictal 50 mg tabletter er påtrykt 'GS SEE1' på den ene side og '50' på den anden side.
Lamictal 50 mg tablets are marked ‘GSEE1' on one side and ‘50' on the other.
Lamictal Dispersible 25mg Starter-Pack Mono
Lamictal Dispersible 25mg Starter-Pack Mono 25 mg Dispersible Tablet
Lamictal 25 mg tabletter er påtrykt 'GS SEC7' på den ene side og '25' på den anden side.
Lamictal 25 mg tablets are marked ‘GSEC7' on one side and ‘25' on the other.
Effekten kan ikke blive opretholdt hos alle børn, der tager lamotrigin for behandling af typiske absencer.
In children taking lamotrigine for the treament of typical absence seizures, efficacy may not be maintained in all patients.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE LAMICTAL
BEFORE YOU TAKE LAMICTAL
Tilføjelse af lægemidler, der IKKE signifikant hæmmer eller inducerer lamotrigin-glukuronideringen (se pkt.
Addition of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation (see section 4.5):
5-15 mg/kg/dag (én gang dagligt eller fordelt på to doser)
5 − 15 mg/kg/day (once a day or two divided doses)
200 mg Tabletter
200 mg Tablet
100-200 mg/dag (én gang dagligt eller fordelt på to doser)
100 − 200 mg/day (once a day or two divided doses)
Hver Lamictal 50 mg tablet indeholder 50 mg lamotrigin.
Each Lamictal 50 mg tablet contains 50 mg lamotrigine.
42 dispergible tabletter / tyggetabletter
42 dispersible/chewable tablets
Behandlingsregimen for lamotrigin tillægsbehandling uden valproat og uden induktorer af lamotrigin glukoronidation bør derfor anvendes hos patienter i samtidig behandling med oxcarbazepin (se pkt.
Therefore in patients receiving concomitant therapy with oxcarbazepine, the treatment regimen for lamotrigine adjunctive therapy without valproate and without inducers of lamotrigine glucuronidation should be used (see section 4.2).
Uge 3 og frem
Week 2 Week 3 onwards
1,2 mg/kg/dag (fordelt på to doser)
1.2 mg/kg/day (two divided doses)
150 mg/dag 225 mg/dag 300 mg/dag
150 mg/day 225 mg/day 300 mg/day
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 100 mg hver eller hver anden uge, indtil den optimale respons er opnået
To achieve maintenance, doses may be increased by maximum of 100 mg every one to two weeks until optimal response is achieved
Pakninger med 10, 14, 28, 30, 50 eller 56 dispergible tabletter / tyggetabletter.
Packs of 10, 14, 28, 30, 50 or 56 dispersible/chewable tablets.
Holland GlaxoSmithKline BV Huis ter Heideweg 62
GlaxoSmithKline BV Huis ter Heideweg 62 3705 LZ Zeist The Netherlands
Finland GlaxoSmithKline Oy Piispansilta 9 A
GlaxoSmithKline Oy Piispansilta 9 A 02230 Espoo Finland
400 mg/dag
400 mg/day
Tillægsbehandling UDEN valproat og UDEN induktorer af lamotrigin-glukuronidering (se pkt.
Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation (see section 4.5):
50 mg Tabletter
50 mg Tablet
Dette dosisregimen skal kombineres med andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin
This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation
Dette dosisregimen skal følges, når andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin, seponeres
This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are withdrawn
Knogler, led, muskler og bindevæv Under kliniske forsøg vedrørende bipolar sygdom: Almindelig:
Musculoskeletal and connective tissue disorders During bipolar disorder clinical trials: Common:
Ataksi.
ataxia.
200 mg/dag 150 mg/dag 100 mg/dag
200 mg/day 150 mg/day 100 mg/day
Diplopi, tågesyn.
diplopia, blurred vision.
Tillægsbehandling UDEN valproat og MED induktorer af lamotrigin-glukuronidering (se pkt.
Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5):
0,6 mg/kg/dag (fordelt på to doser)
0.6 mg/kg/day (two divided doses)
• Hududslæt eller rødme
• skin rashes or redness
200 mg/dag
200 mg/day
100 mg Tabletter
100 mg Tablet
I undersøgelser, der havde til formål at vurdere lægemidlers effekt på centralnervesystemet, afveg de opnåede resultater ved brug af doser på 240 mg lamotrigin administreret til raske frivillige ikke fra de opnåede resultater ved brug af placebo.
In tests designed to evaluate the central nervous system effects of medicinal products, the results obtained using doses of 240 mg lamotrigine administered to healthy volunteers did not differ from placebo, whereas both 1000 mg phenytoin and 10 mg diazepam each significantly impaired fine visual motor co-ordination and eye movements, increased body sway and produced subjective sedative effects.
300 mg/dag 225 mg/dag 150 mg/dag
300 mg/day 225 mg/day 150 mg/day
Lamictal Dispersible 50mg Starter-Pack add-on
Lamictal Dispersible 50mg Starter-Pack add-on 50 mg Dispersible Tablet
Pakninger med 10, 14, 21, 28, 30, 42, 50, 56 eller 60 dispergible tabletter / tyggetabletter.
Packs of 10, 14, 21, 28, 30, 42, 50, 56 or 60 dispersible/chewable tablets.
28 dispergible tabletter / tyggetabletter
28 dispersible/chewable tablets
Pakninger med 14, 30, 42, 56, 90 eller 100 tabletter.
Packs of 14, 30, 42, 56, 90 or 100 tablets.
100 mg/dag 150 mg/dag 200 mg/dag
100 mg/day 150 mg/day 200 mg/day
Pakninger med 10, 30, 50, 56, 60, 90, 100 eller 200 dispergible tabletter / tyggetabletter.
Packs of 10, 30, 50, 56, 60, 90, 100 or 200 dispersible/chewable tablets.
4.5) afhængigt af den oprindelige dosis lamotrigin:
Withdrawal of inducers of lamotrigine glucuronidation (see section 4.5), depending on original dose of lamotrigine:
Hver pakning med blistere indeholder 10, 14, 21, 28, 30, 42, 50, 56 eller 60 tabletter.
Each pack contains blisters of 10, 14, 21, 28, 30, 42, 50, 56 or 60 tablets.
300 mg/dag
300 mg/day
100 mg/dag (fordelt på to doser)
100 mg/day (two divided doses)
200 dispergible tabletter / tyggetabletter
200 dispersible/chewable tablets
Indehaver af markedsføringstilladelsen: [Se bilag I - udfyldes nationalt]
Marketing Authorisation Holder: [See Annex I - To be completed nationally]
Seponering af lægemidler, der IKKE signifikant hæmmer eller inducerer glukuronidering af lamotrigin (se pkt.
Withdrawal of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation (see section 4.5):
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 50-100 mg hver eller hver anden uge, indtil den optimale respons er opnået
To achieve maintenance, doses may be increased by maximum of 50 - 100 mg every one to two weeks until optimal response is achieved
Natriumstivelsesglycolat (type A) Povidon K30
Low-substituted hydroxypropyl cellulose Aluminium magnesium silicate Sodium starch glycolate (Type A) Povidone K30
Lamictal Dispersible 25mg Starter-Pack Add-on
Lamictal Dispersible 25mg Starter-Pack Add-on 25 mg Dispersible Tablet
200 mg/dag (fordelt på to doser)
200 mg/day (two divided doses)
50 mg/dag (én gang dagligt eller fordelt på to doser)
50 mg/day (once a day or two divided doses)
Hos patienter, der tager lægemidler, hvor den farmakokinetiske interaktion med lamotrigin ikke kendes på nuværende tidspunkt (se pkt.
In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate, should be used.
- Spørg lægen eller på apoteket, hvis der er mere, du vil vide.
Check with your doctor or pharmacist if you're not sure.
21 dispergible tabletter / tyggetabletter
21 dispersible/chewable tablets
Pakninger med 10, 14, 30, 42, 50, 56, 60, 90, 100 eller 200 dispergible tabletter / tyggetabletter.
Packs of 10, 14, 30, 42, 50, 56, 60, 90, 100 or 200 dispersible/chewable tablets.
Der findes startpakninger med 21 eller 42 tabletter til de første uger af behandlingen, hvor dosis langsomt øges.
Starter packs containing 21 or 42 tablets are available for use during the first few weeks of treatment when the dose is being slowly increased.
50 dispergible tabletter / tyggetabletter
50 dispersible/chewable tablets
Î Spørg lægen til råds om, hvordan du skal fortsætte behandlingen.
If you have missed taking a dose of Lamictal: Î Ask your doctor for advice on how to start taking it again.
56 dispergible tabletter / tyggetabletter
56 dispersible/chewable tablets
Hver Lamictal 2 mg dispergibel tablet / tyggetabletindeholder 2 mg lamotrigin.
Each Lamictal 2 mg dispersible/chewable tablet contains 2 mg lamotrigine.
Hver pakning med blistere indeholder 14, 21, 30, 42, 50, 56 eller 100 tabletter.
Each pack contains blisters of 14, 21, 30, 42, 50, 56 or 100 tablets.
Lamictal og tilknyttede navne (se bilag I) 25 mg tabletter.
Lamictal and associated names (see Annex I) 25 mg tablets.
100 mg/dag (én gang dagligt eller fordelt på to doser)
100 mg/day (once a day or two divided doses)
Hver pakning med blistere indeholder 10, 14, 30, 42, 50, 56, 60, 90, 100 eller 200 tabletter.
Each pack contains blisters of 10, 14, 30, 42, 50, 56, 60, 90, 100 or 200 tablets.
Hver Lamictal 100 mg dispergibel tablet / tyggetabletindeholder 100 mg lamotrigin.
Each Lamictal 100 mg dispersible/chewable tablet contains 100 mg lamotrigine.
90 dispergible tabletter / tyggetabletter
90 dispersible/chewable tablets
Under kliniske forsøg vedrørende bipolar sygdom: Meget almindelig:
Nervous system disorders During bipolar disorder clinical trials: Very common:
14 dispergible tabletter / tyggetabletter
14 dispersible/chewable tablets
Hver Lamictal 200 mg dispergibel tablet / tyggetabletindeholder 200 mg lamotrigin.
Each Lamictal 200 mg dispersible/chewable tablet contains 200 mg lamotrigine.
Lamictal og tilknyttede navne (se bilag I) 100 mg tabletter.
Lamictal and associated names (see Annex I) 100 mg tablets.
Hver Lamictal 5 mg dispergibel tablet / tyggetabletindeholder 5 mg lamotrigin.
Each Lamictal 5 mg dispersible/chewable tablet contains 5 mg lamotrigine.
Der er ikke foretaget undersøgelser af interaktionen mellem andre perorale kontraceptiva eller hormonsubstitutionsbehandlinger og lamotrigin.
The interaction between other oral contraceptive or HRT treatments and lamotrigine have not been studied, though they may similarly affect lamotrigine pharmacokinetic parameters.
30 dispergible tabletter / tyggetabletter
30 dispersible/chewable tablets
Under kliniske forsøg med monoterapi: Meget almindelig:
Nervous system disorders During monotherapy clinical trials: Very common:
Der findes også startpakninger med 21 eller 42 tabletter til de første uger af behandlingen, hvor dosis langsomt øges.
Starter packs containing 21 or 42 tablets are also available for use during the first few weeks of treatment when the dose is being slowly increased.
INDEHAVER AF MARKEDSFØRINGSTILLADELSEN [Se bilag I - udfyldes nationalt]
MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
100 dispergible tabletter / tyggetabletter
100 dispersible/chewable tablets
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 0,6 mg/kg hver eller hver anden uge, indtil den optimale respons er opnået, og vedligeholdelsesdosis må maksimalt være 200 mg/dag Hos patienter, der tager lægemidler, hvor den farmakokinetiske interaktion med lamotrigin ikke kendes på nuværende tidspunkt (se pkt.
To achieve maintenance, doses may be increased by maximum of 0.3 mg/kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 200 mg/day Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5): This dosage regimen should be used without valproate but with:
Lamictal og tilknyttede navne (se bilag I) 200 mg tabletter.
Lamictal and associated names (see Annex I) 200 mg tablets.
Under kliniske forsøg vedrørende bipolar sygdom: Almindelig:
Gastrointestinal disorders During bipolar disorder clinical trials: Common:
Hver pakning med blistere indeholder 14, 30, 42, 56, 90 eller 100 tabletter.
Each pack contains blisters of 14, 30, 42, 56, 90 or 100 tablets.
1-10 mg/kg/dag (én gang dagligt eller fordelt på to doser)
1 − 10 mg/kg/day (once a day or two divided doses)
0,3 mg/kg/dag (én gang dagligt eller fordelt på to doser)
0.3 mg/kg/day (once a day or two divided doses)
60 dispergible tabletter / tyggetabletter
60 dispersible/chewable tablets
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 200 mg lamotrigin
STATEMENT OF ACTIVE SUBSTANCE Each tablet contains 200 mg lamotrigine
Der findes startpakninger med 42 tabletter til de første uger af behandlingen, hvor dosis langsomt øges.
Starter packs containing 42 tablets are available for use during the first few weeks of treatment when the dose is being slowly increased.
De er påtrykt 'GS CL5' på den ene side og '25' på den anden side.
They are marked ‘GSCL5' on one side; and ‘25' on the other.
Hver Lamictal 25 mg dispergibel tablet / tyggetabletindeholder 25 mg lamotrigin.
Each Lamictal 25 mg dispersible/chewable tablet contains 25 mg lamotrigine.
10 dispergible tabletter / tyggetabletter
10 dispersible/chewable tablets
GlaxoSmithKline ehf Thverholt 14
Thverholt 14
Lamictal og tilknyttede navne (se bilag I) 50 mg tabletter.
Lamictal and associated names (see Annex I) 50 mg tablets.
Lavere vedligeholdelsesdoser kan være effektive hos patienter med signifikant nedsat nyrefunktion (se pkt.
For patients with end-stage renal failure, initial doses of lamotrigine should be based on patients' concomitant medicinal products; reduced maintenance doses may be effective for patients with significant renal functional impairment (see sections 4.4 and 5.2).
Hver pakning med blistere indeholder 30, 50, 56, 60, 90 eller 100 tabletter.
Each pack contains blisters of 30, 50, 56, 60, 90 or 100 tablets.
0,6 mg/kg/dag (én gang dagligt eller fordelt på to doser)
0.6 mg/kg/day (once a day or two divided doses)
Lamictal 25 mg disperzibilne/žvečljive tablete
Lamictal 25 mg disperzibilne/žvečljive tablete 25 mg Dispersible/Chewable Tablet
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 100 mg lamotrigin
STATEMENT OF ACTIVE SUBSTANCE Each tablet contains 100 mg lamotrigine
1-5 mg/kg/dag (én gang dagligt eller fordelt på to doser)
1 − 5 mg/kg/day (once a day or two divided doses)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 25 mg lamotrigin
STATEMENT OF ACTIVE SUBSTANCE Each tablet contains 25 mg lamotrigine
Smerter, rygsmerter.
pain, back pain.
Lamictal 200 mg disperzibilne/žvečljive tablete
Lamictal 200 mg disperzibilne/žvečljive tablete 200 mg Dispersible/Chewable Tablet